The objective of this study was to determine if the maternal serum levels of visfatin in the first trimester of pregnancy are altered in cases that develop preeclampsia (PE) and whether the levels are related to placental perfusion reflected in uterine artery pulsatility index (PI). Serum visfatin and uterine artery PI were measured at 11 þ 0 -13 þ 6 weeks in 80 cases that developed PE and 240 unaffected controls. The median visfatin and uterine artery PI multiple of the unaffected median (MoM) in the outcome groups was compared and the significance of the association between visfatin MoM and uterine artery PI MoM, birth weight percentile and gestation at delivery was determined. In the PE group, compared with controls, there was a significantly higher median visfatin MoM (1.35, interquartile range (IQR): 0.69-2.16 vs 1.00, IQR: 0.55-1.96, P ¼ 0.027) and uterine artery PI MoM (1.19, IQR: 0.95-1.44 vs 1.03, IQR: 0.83-1.22, Po0.0001). In the PE group, there was no significant association between serum visfatin MoM and uterine artery PI MoM (P ¼ 0.589), gestation at delivery (P ¼ 0.763) or birth weight percentile (P ¼ 0.646). Serum visfatin levels at 11-13 weeks are increased in women who develop PE by a mechanism unrelated to impaired placental perfusion.
INTRODUCTION
Visfatin is an adipokine preferentially produced by visceral adipose tissue, but in pregnancy it is also expressed in the placenta and fetal membranes. 1 It has insulinomimetic and immunoregulatory properties and increased circulating concentrations have been reported in insulin-resistant states, including obesity, type II diabetes mellitus and gestational diabetes. [1] [2] [3] [4] [5] [6] [7] [8] In pregnancies with established preeclampsia (PE) the maternal circulating levels of visfatin are usually increased, [9] [10] [11] but in some studies the levels were decreased 12 or not different from normal. 13 These contradictory results may be the consequence of differences in the populations examined and the heterogeneous nature of PE. There is evidence that severe early-onset PE is due to impaired placentation manifested with increased pulsatility index (PI) in the uterine arteries, [14] [15] [16] whereas in late PE the main pathophysiological processes resemble those of the metabolic syndrome with increased insulin resistance. [17] [18] [19] [20] [21] In the context of PE, visfatin could be a biomarker of both the metabolic syndrome, where the circulating levels are known to be increased, and of impaired placentation. One study reported that in patients with PE the levels of visfatin were significantly higher in those with increased impedance to flow in the uterine arteries than in those with normal uteroplacental perfusion. 10 The aim of this study is to investigate further the association between visfatin and PE by measuring the maternal serum levels in the first trimester of pregnancy, before the clinical onset of the disease, and examining the possible association with alterations in placental perfusion.
MATERIALS AND METHODS

Study population
This was a case-control study drawn from a large prospective observational study for early prediction of pregnancy complications in women attending for their routine first hospital visit in pregnancy at King's College Hospital, London, UK. In this visit, which was held at 11 þ 0 -13 þ 6 weeks of gestation, we recorded maternal characteristics and medical history and performed combined screening for aneuploidies by measurement of the fetal crown-rump length and nuchal translucency thickness and maternal serum pregnancy-associated plasma protein-A and free beta-human chorionic gonadotropin. [22] [23] [24] We measured the uterine artery PI by transabdominal pulsed Doppler and recorded the mean value. 16 Written informed consent was obtained from the women agreeing to participate in the study, which was approved by King's College Hospital ethics committee.
In this study, we measured maternal serum visfatin in 80 cases that developed PE and 240 unaffected controls who did not develop any hypertensive disorder of pregnancy and delivered a phenotypically normal neonate at term with weight appropriate for gestational age. Cases were selected at random from our database of stored samples and for each case we selected three controls that were sampled on the same day.
Outcome measures
Data on pregnancy outcome were obtained from the maternity computerized records or the general medical practitioners of the women and were recorded in our database. The obstetric records of all women with pre-existing or pregnancy-associated hypertension were examined to determine if the condition was chronic hypertension, PE or gestational hypertension. The definition of PE was that of the International Society for the Study of Hypertension in Pregnancy. 25 The systolic blood pressure should be 140 mm Hg or more and/or the diastolic blood pressure should be 90 mm Hg or more on at least two occasions 4 h apart developing after 20 weeks of gestation in previously normotensive women and there should be proteinuria of 300 mg or more in 24 h or two readings of at least þþ on dipstick analysis of midstream or catheter urine specimens if no 24 h collection is available. In PE superimposed on chronic hypertension significant proteinuria (as defined above) should develop after 20 weeks of gestation in women with known chronic hypertension (history of hypertension before conception or the presence of hypertension at the booking visit before 20 weeks of gestation in the absence of trophoblastic disease).
Sample analysis
None of the samples in this study were previously thawed and refrozen. Maternal serum visfatin concentration was measured by a quantitative ELISA (enzyme-linked immunoassay) technique using Visfatin (eNampt/ PBEF) ELISA kit (44-VISHU-E01.4, Alpco Diagnostics, Salem, NH, USA). The lower limit of detection of the assay was 0.03 ng ml À 1 . The intra-assay and inter-assay coefficient of variation (CV) ranged from 2.3% to 9.1% and 4.7% to 7.2%, respectively. All samples were analyzed in duplicate and those with a CV exceeding 10% were reanalyzed.
Statistical analysis
Comparison between PE and control groups was done by Mann-Whitney U-test for continuous variables and w 2 test or Fisher's exact test for categorical variables.
The distribution of serum visfatin was made Gaussian after logarithmic 10 transformation. In the unaffected controls, Gaussian normality was examined using probability plots and Shapiro-Wilk test (W ¼ 0.990, P ¼ 0.106). The distributions of uterine artery PI were made Gaussian after logarithmic 10 transformation. Multiple regression analysis in the unaffected controls demonstrated that none of the maternal characteristics affected the maternal serum concentration of visfatin and the values in each case and control were expressed as multiple of the median (MoM) in the control group. In each case and control, the measured uterine artery PI were converted into MoMs after adjustment for gestation, maternal age, racial origin, maternal weight and smoking as previously described. 26 MannWhitney U-test was used to compare median MoM values of visfatin and uterine artery PI between the PE and control groups. Non-parametric analysis was used to examine the significance of association between maternal serum visfatin, uterine artery PI, gestation at delivery and birth weight percentile in the outcome groups.
The statistical software package SPSS 16.0 (SPSS Inc., Chicago, IL, USA) was used for data analyses.
RESULTS
The maternal characteristics of the PE and control groups are compared in Table 1 . In the PE group, the median maternal weight was higher, more women had PE in their previous pregnancies, required assisted conception techniques, had chronic hypertension and delivered neonates with a lower birth weight percentile.
Multiple regression analysis in the unaffected controls demonstrated that for log 10 visfatin there were no significant contributions provided by maternal age (P ¼ 0.412), maternal weight (P ¼ 261), maternal height (P ¼ 0.468), smoking status (P ¼ 0.658), method of conception (P ¼ 0.270), parity (P ¼ 0.922), racial origin (P ¼ 0.394) or fetal crown-rump length (P ¼ 0.664).
In the PE group, compared with controls, there was a significantly higher median visfatin MoM (1. Table 2 ). In the PE group, there were 8 women with chronic hypertension who developed superimposed PE. The increase in serum visfatin MoM and uterine artery PI still remained significant even after excluding the women with chronic hypertension who developed PE (P ¼ 0.041, Po0.0001).
There was no significant association between maternal serum visfatin MoM and uterine artery PI MoM, gestation at delivery or birth weight percentile in either the PE group (P ¼ 0.589, P ¼ 0.763 and P ¼ 0.646, respectively) or the control group (P ¼ 0.821, P ¼ 0.085 and P ¼ 0.669, respectively). In contrast, in the PE group there was a significant association between uterine artery PI MoM and both gestation at delivery (Spearman's coefficient (r) ¼ -0.335, P ¼ 0.002) and birth weight percentile (r ¼ À 0.427, Po0.0001), but not in controls (P ¼ 0.137 and P ¼ 0.948, respectively). The median maternal BMI was significantly higher in the PE group compared with the control group (27.3 vs 23.1, Po0.0001) but regression analysis demonstrated that there was no significant association between log 10 visfatin and BMI in either the control (P ¼ 0.166) or the PE groups (P ¼ 0.936) (Figure 1 ).
DISCUSSION
The finding of this study that in pregnancies which develop PE maternal serum visfatin levels are increased is compatible with the results of previous studies in pregnancies with established disease. 10, 11, 28 As the increase in visfatin is apparent from the first trimester of pregnancy, this adipokine may be implicated in the pathogenesis of PE. There is extensive evidence that the underlying mechanism for early PE is impaired trophoblastic invasion of the maternal spiral arteries, reduced placental perfusion and fetal growth restriction. [14] [15] [16] In late PE, placental perfusion and fetal growth are often normal and the main pathophysiological processes resemble those of the metabolic syndrome with an increase in adipose tissue and impaired glucose and lipid metabolism. 20, 21, 28 The possibility that visfatin may be implicated in placentation was raised by the finding that this protein is expressed in the placenta and fetal membranes 1 and the results of a study in women with established PE which reported that the levels of visfatin were higher in those with Doppler evidence of increased rather than normal impedance to flow in the uterine arteries. 10 However, in our study although uterine artery PI in the pregnancies that developed PE was increased, there was no significant association between serum visfatin and uterine artery PI or gestation at delivery suggesting that the increase in visfatin is unlikely to be mediated by impaired placental perfusion.
Circulating levels of visfatin are increased in insulin-resistant states and in women who develop gestational diabetes mellitus the increased levels are apparent from the first trimester of pregnancy. 29 It is therefore likely that visfatin is implicated in a metabolic disorder-mediated pathogenesis of PE. Visfatin is a marker of endothelial damage 30, 31 and such damage is observed in both early and late onset PE. 21 Visfatin has a variable effect on vascular tissue. Although chronic exposure to high visfatin levels, such as in obesity and in type 2 diabetes mellitus, promotes endothelial dysfunction, acute administration of visfatin stimulates endothelial nitric oxide synthetase expression and activity. 32 Animal studies reported that visfatin inhibits the contractility of vascular smooth muscle in a concentration-dependent manner and induces an NO-mediated vasodilatation. 33 It could therefore be postulated that in both early and late PE there is impaired placentation and uterine artery PI should be increased. However, in women with insulin-resistant states, who are at increased risk of developing late PE, there is visfatin-mediated vasodilatation with consequent maintenance of uterine artery PI within the normal range. An alternative explanation for the finding of increased serum visfatin in both early and late PE is that release of visfatin occurs in response to endothelial dysfunction. In early PE, endothelial cell activation and damage are the consequence of impaired trophoblastic invasion of the maternal spiral arteries, which leads to placental ischemia and the release of inflammatory factors, [34] [35] [36] whereas in late PE endothelial dysfunction is related to the metabolic syndrome and possible lipid dysfunction. 37 The strength of our study is the examination of a large number of pregnancies that developed PE within a narrow window at 11-13 weeks, which is emerging as the gestation of choice for risk assessment for a wide range of pregnancy complications. 38 The concomitant measurement of uterine artery PI allowed assessment of the possible mechanisms implicating visfatin in the pathogenesis of PE. The main weakness of our study resides in the design, which was case-control. A prospective longitudinal study from the first trimester to the development of PE would provide more insight into the role of this protein in the pathogenesis of the disease.
What is known about this topic
Visfatin is a protein produced by visceral adipose tissue, but in pregnancy it is also expressed in the placenta and fetal membranes.
In pregnancies with established preeclampsia, the maternal circulating levels of visfatin are usually increased.
What this study adds Serum visfatin levels at 11-13 weeks' gestation are increased in women who develop preeclampsia. Visfatin could be implicated in the pathogenesis of preeclampsia. 
